SCHEMBL9218324

SCHEMBL9218324

N#CN=C(N)c1ccsc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.55
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
DAO P14920 1/20 0.41
ADRA2A P08913 2/20 0.38
ADRA2B P18089 2/20 0.38
ADRA2C P18825 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
ALOX12 P18054 2/20 0.38
HTT P42858 1/20 0.38
HDAC1 Q13547 1/20 0.37
MAPT P10636 5/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1544143 0.77
SCHEMBL14625427 0.75
SCHEMBL9211615 0.73 MAPT (0.40) POLBCES2CES1LCKFYN
SCHEMBL9211607 0.73 MAPT (0.40) POLBCES2CES1LCKFYN
SCHEMBL18419421 0.71 POLB (1.00) POLBALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL11229878 0.71 POLB (1.00) POLBALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL11167783 0.69 RECQL (0.52) POLBCES2CES1LCKFYN
SCHEMBL15494356 0.69 CES2 (0.50) POLBCES2CES1LCKFYN
SCHEMBL9220145 0.68 POLB (0.64) POLBALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL6704860 0.68 CES2 (0.45) POLBCES2CES1LCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479856-B2 Pharmaceutical compounds for the treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2025-11-25 US disclosed
US-20230085372-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2023-03-16 US disclosed
EP-0388528-B1 Carboximidamide derivatives KIRIN BREWERY (JP) 1995-09-27 EP disclosed
US-5272164-A Carboximidamide derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 1993-12-21 US disclosed
US-5223508-A Hypotensive agents, vasodilators KIRIN BEER KABUSHIKI KAISHA (JP) 1993-06-29 US disclosed
US-5166347-A Hypotensive agents, cardiovascular disorders, antiischemic agents and anticoagulants KIRIN BEER KABUSHIKI KAISHA (JP) 1992-11-24 US disclosed
EP-0388528-A2 Carboximidamide derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 1990-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479856-B2 Pharmaceutical compounds for the treatment of complement mediated disorders C5, CFH, C1QBP POLB 2639/4885CES2 1499/4885CES1 1010/4885
US-20230085372-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, CFH, C1QBP POLB 2639/4885CES2 1499/4885CES1 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.